Search Results

1 - 10 of 107 items :

  • "rituximab" x
Clear All
Maintenance Therapy with Rituximab in Adult Patients with Immune Thrombocytopenia

, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350: 2572-2581. 16. Ahmed ER, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355: 1772-1779. 17. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2004;103: 2925-2928. 18. Arnold DM, Dentali F, Crowther MA, et al. Systematic review

Open access
Original article. Correlation of FcγRIIIa polymorphisms and responses to rituximab in Thai population

References 1. Zhong Y. Non-Hogkin’s lymphoma: what primary care professionals need to know. J Nurse Pract. 2006; 2:309-15. 2. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. The Lancet Oncol. 2004; 5: 341-53. 3. Lu P. Staging and classification of lymphoma. Semin Nucl Med. 2005; 35:160-4. 4. Sacchi S, Federico M, Dastoli G, Fiorani C, Vinci G, Clo‘ V, et al. Treatment of B-cell non-Hodgkin’s lymphoma with anti CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol. 2001

Open access
Clinical And Morphological Improvement Of Lupus Nephritis Treated With Rituximab

REFERENCES 1. Klyukvina NG, Nasonov EL, Nasonova VA. Systemic Lupus Erythematosus. In: Rheumatology, National Guidance Manual. Moscow: GEOTAR; 2008:419-46 (Russian). 2. Condon M, Ashby D, Pepper R, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6. 3. Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus

Open access
Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

References http://medical-dictionary.thefreedictionary.com/lymphoproliferative Primic Žakelj M, Bračko M, Hočevar M, Pompe-Kirn V, Strojan P, Zadnik V, Zakotnik B and Žagar T, editors. Cancer incidence in Slovenia 2006. Ljubljana: Institute of Oncology Ljubljana, Cancer registry of Republic of Slovenia; 2009. Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 2006; 66 : 791

Open access
Thrombotic Thrombocytopenic Purpura: Etiopathogenesis, Diagnostics and Basic Principles of Treatment

;158(3):323-35. 44. Balduini CL, Gugliotta L, Luppi M, et al; Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89(6):591-596. 45. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746-1753. 46. Froissart A, Buffet M, Veyradier A, et al. Efficacy and safety of first-line rituximab in

Open access
Research advances in reactivation of hepatitis virus after chemotherapy for non-Hodgkin’s lymphoma-combined hepatitis B virus infection

Cancer, 2001, 16(2):181. 4 Kin JH, Bang YJ, Parb J, et al . Hepatitis B virus infection and B-cell non-Hodgkin’ s lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res, 2002, 93(5): 47l-477. 5 Guan Z, Wang S. Research Status of Chemotherapy for B Cell Lymphoma. Chinese Journal of Oncology, 2005, 27(12):760-761. 6 Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomised controlled

Open access
Testing of mechanisms of action of rituximab and clinical results in high-risk patients with aggressive CD20+ lymphoma

References Lucas BJ, Horning SJ. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage JO, Longo DL, editors. Annual of Lymphoid Malignancies. London: Martin Dunitz Ltd; 2001. p. 153-67. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24 : 2121-43. Maloney DG, Liles TM, Czerwinski

Open access
Cerebral toxoplasmosis in a diffuse large B cell lymphoma patient

and she was started on chemotherapy with rituximab and chlorambucil (R-LP), but was switched after only two cycles of R-LP to fludarabine and cyclophosphamide in combination with rituximab (R-FC) due to further disease progression. During this time, she suffered an episode of cutaneous herpes zoster, so valacyclovir prophylaxis was initiated. In January 2013, a transformation into DLBCL was confirmed and rituximab, cyclophosphamide, vincristine, doxorubicin and prednisolone (R-CHOP) chemotherapy regimen introduced. After 4 cycles of R-CHOP, disease remission was

Open access
Stosowanie leków biopodobnych w hematoonkologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów

Agency Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues London: European Medicines Agency; 2014 1 13 [7] Jurczak W, Moreira I, Kanakasetty GB, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol 2017;4:e350–61. 10.1016/S2352-3026(17)30106-0 28712941 Jurczak W Moreira I

Open access
Secondary antibody deficiency and immunoglobulin replacement

various common drugs implicated in iatrogenic HG are summarized in Table 1 . This list continues to expand with the rapid development of novel immunosuppressive and biologic therapies. In particular, the increasing popularity of anti-CD20 therapies, such as rituximab, has led to increasing reports of secondary antibody deficiency and fueled more research into its significance and treatment. Table 1 Common examples of drug-induced hypogammaglobinemia Anti-epileptics Immunosuppressants Monoclonal antibodies Others Carbamazepine

Open access